As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in tandem thanks to advancements in technology and a growing body of research on ...

FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ...

This important Research Advance presents convincing evidence on the neuroprotective effects of reserpine in a well-established model of retinitis pigmentosa (P23H-1 ... to characterize sex- bias ...

Retinitis pigmentosa is a relatively rare genetic disorder (affecting 1 in 3,500 people), while age-related macular degeneration affects 7–8% of the population, and its incidence increases with age.

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 in the open-access ...

"These findings illuminate a critical mechanism that connects local synaptic activity to the broader gene expression changes necessary for learning and memory," said Mark Dell'Acqua, professor of ...

VP-001 is under clinical development by PYC Therapeutics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa (Retinitis) have ...

Today, Canada alongside other G7 RRM members (European Union, France, Germany, Italy, Japan, the United Kingdom, the United States) as well as G7 RRM Observer states (Australia, Netherlands, New ...

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding th ...

OCU400 showed significant 2-line gain in LLVA in treated eyes, validating its gene-agnostic mechanism for retinitis pigmentosa. The therapy's effectiveness across multiple mutations highlights its ...